Steven Peskin, MD, MBA, FACP: Diagnostic tools in cancer—that’s a broad range. We, most recently, have thought about and have focused on molecular diagnostics, companion diagnostics, and the explosion in genetic testing and proteomic testing. We see some very real value.
On the other hand, there are a range of tests that have a questionable impact on the course of treatment. In fact, some of these tests can, metaphorically speaking, take one’s eye off the ball. We see that the explosion in the number of genetic molecular tests can be a cause for some overuse and inappropriate use, and again, can take us down pathways that are not in the patient’s best interest. I’ve had oncologists who know far more about this area than me express that to me as well.
There are other diagnostics. There’s the use of advanced imaging. We know that some advanced imaging is very vital. On the other hand, in certain stable breast cancer patients, for example, there’s no evidence to support repeat PET/CT (positron emission tomography and computed tomography) scans. That’s another area where we’re cognizant of working toward appropriate use.
How might we support clinicians around clinical pathways? We do not have proscribed clinical pathways that we have endorsed, or [that we are] working with a third party organization on, as some health plans that have developed pathways in cancer care do. We do provide our clinical partners with our medical policy. That reflects a lot of time, effort, energy, and thoughtfulness by clinicians with input from community thought leaders. We do provide analytics to our clinical partners. Increasingly, we’re taking what we have in the area of medical economics, analytics, and health information, to work with or harmonize that with our clinical organizations. But, we do not have explicit or proscribed clinical pathways. We do provide feedback to our clinical partners. In certain areas of cancer (chronic lymphocytic leukemia [CLL] is not one of them), we do have episode of care models that we have endorsed.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
UK Study: Most Patients With MG Require Hospitalization, Driving Health Care Resource Use
April 27th 2024Over a median follow-up time of nearly 3 years, three-fourths (72.8%) of patients with myasthenia gravis (MG) were hospitalized and half visited the accident and emergency department.
Read More
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More